Trinity Capital Inc. (TRIN)
After hours:
| Previous close | 14.78 |
| Open | 14.80 |
| Bid | 14.81 x 200 |
| Ask | 14.86 x 100 |
| Day's range | 14.77 - 14.84 |
| 52-week range | 12.34 - 15.44 |
| Volume | |
| Avg. volume | 480,854 |
| Market cap | 733.766M |
| Beta (5Y monthly) | 0.67 |
| PE ratio (TTM) | 9.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.04 (13.80%) |
| Ex-dividend date | 27 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Trinity Capital Inc. Expands Operations into Europe
Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity" or the "Company"), a leading provider of diversified financial solutions to growth-oriented companies, today announced its strategic expansion into Europe with the appointment of London-based Craig Fox as Managing Director. This initiative aligns with the Company's long-term vision of supporting high-growth companies globally.
- PR Newswire
Metabolon Secures $60 Million Credit Facility to Drive Growth and Innovation
Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announced that it has closed on a new $60 million credit facility. This significant investment, of which an initial $42.5 million was funded at closing, will be utilized to fuel the company's growth initiatives and expand its research and development efforts to further enhance its metabolomics platform.
- PR Newswire
Trinity Capital Inc. Provides $60 Million in Growth Capital to Metabolon
Trinity Capital Inc. (NASDAQ: TRIN) ("Trinity"), a leading provider of diversified financial solutions to growth-stage companies, today announced the commitment of $60 million in growth capital to Metabolon, a global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications.
